Brief: PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo
09/09/2026 18:18
BRIEF-PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo Sept 9 (Reuters) - PureTech Health PLC PRTC.L:
PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 1 DRIVING SIMULATION TRIAL OF GLYPHALLO™ IN HEALTHY VOLUNTEERS
PURETECH HEALTH: GLYPHALLO 375 MG DID NOT IMPAIR NEXT-MORNING DRIVING PERFORMANCE ON DAY 5
PURETECH HEALTH - ENROLLING BUOY-1 PHASE 2B TRIAL FOR GLYPHALLO IN MDD; TOPLINE DATA EXPECTED H1 2027
PURETECH HEALTH: TO SUBMIT GLYPHALLO PHASE 1 RESULTS TO U.S. FDA
PURETECH HEALTH: GLYPHALLO WAS WELL-TOLERATED, WITH NO SERIOUS ADVERSE EVENTS REPORTED
PURETECH HEALTH - GLYPHALLO 250 MG DID NOT IMPAIR NEXT-MORNING DRIVING PERFORMANCE ON DAY 2
Source text: ID:nBw6LRwz4a
Further company coverage: PRTC.L
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Seaport Therapeutics
See all newsBrief: PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo
Brief: Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers
Biotech firm Odyssey raises $279 million in upsized US IPO (updated)